Notwithstanding recent studies that have provided evidence of the overall safety of starting treatment with insulin in the general T2DM population without increasing the risk of overall mortality and major adverse cardiovascular events [33], the increasing insulin dosage in patients with concomitant heart failure was associated with poor clinical outcomes [34]. This evidence concerns the gene INS and heart failure.